Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Hexion's decision to acquire technology capabilities rather than building them internally was driven by two factors: speed-to-market and de-risking commercialization. Buying a business with an existing or near-commercial product provides a significant head start and avoids the uncertainty of a long, internal development cycle.

Large companies rarely make cold acquisition offers. The typical path is a gradual process starting with a partnership or a small investment. This allows the acquirer to conduct due diligence from the inside, understand the startup's value, and build relationships before escalating to a full buyout.

A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

Zevra accelerated its transition to a commercial-stage company by acquiring Acer Therapeutics. This strategic move provided a foundational commercial team, specialty pharmacy contracts, and patient advocacy relationships, de-risking their upcoming drug launch by avoiding the distraction of building it all from scratch.

The old assumption that small biotechs struggle with commercialization ("short the launch") is fading. Acquirers now target companies like Verona and Intracellular that have already built successful sales operations. This de-risks the acquisition by proving the drug's market viability before the deal, signaling a maturation of the biotech sector.

Chandra Dev Mehta explains how Hexion uses M&A to pivot from a traditional chemical company into a 'technology focused chemicals as a service' business. This strategic use of acquisitions helps them escape the challenges of the commodity sector by adding a recurring service and technology layer to their offerings.

A-muto initially acted as an analytical partner for top pharma companies. This revenue-generating model served a strategic purpose: it validated their platform with key customers, funded development, and built trust. This foundation enabled them to transition smoothly into higher-value co-discovery and co-development deals.

PathoQuest's survival depended on a difficult strategic pivot. The company had to abandon its initial, ambitious goal of developing clinical diagnostics for infectious diseases to focus solely on providing QC services to the pharma industry. The CEO admitted that without this tough decision, the company would have failed.